Yahoo Finance

UBS raised the firm’s price target on BioMarin (BMRN) to $106 from $104 and keeps a Buy rating on the shares. BioMarin reported a solid quarter and guidance was raised incrementally on the top and bottom line, the analyst tells investors in a research note. The firm thinks the enzyme replacement therapy business alone is worth at/above where shares are trading, and thinks BMN333, which is entering the clinic in early 2025, could be a significant value driver for BioMarin in both retaining share in achon and in expanding to further indications where Voxzogo is currently being studied.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on BMRN:

• BioMarin price target lowered to $84 from $93 at Canaccord

• BioMarin price target lowered to $65 from $72 at Baird

• BioMarin price target lowered to $81 from $93 at Citi

• BioMarin price target lowered to $109 from $110 at JPMorgan

• William Blair downgrades BioMarin to Market Perform on lack of catalysts